A new drug marks pivotal findings in the study of oncology.
While cancer today is treated on an organ -based manner, new medicines target the cancer cell’s genetic composite instead.
‘Vitrakvi’ is the name of the drug newly approved by the American Food and Drug Authority (FDA).
Changes within the DNA of our body can change the behavior of a normal cell and turn it into a cancer.
The oral medication targets this genetic change.
In an exclusive interview with Al – Arabiya, Dr. Stephen Liu explains how the new treatment is the “optimal choice” for some cancer patients.
The pill only works on a specific genetic change, which is only found in 1% of the patients. To test for the genetic change, a patient must undergo a lengthy and expensive assessment that can cost to up to $ 400,000.
New technological advances will help the treatment become more accessible in the future.